Related Experiment Video
Updated: Jul 17, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.
Sang Hoon Han1, Se Hoon Park, Jung Ho Kim
1Department of Internal Medicine, Gachon Medical School Gil Medical Center, Incheon, Korea.
The Korean Journal of Internal Medicine
|January 26, 2007
Summary
Thalidomide showed potential for disease stabilization in patients with metastatic hepatocellular carcinoma (HCC) refractory to chemotherapy. Further research into dose escalation or combination therapies is warranted for this difficult-to-treat cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic hepatocellular carcinoma (HCC) presents a significant treatment challenge.
- Thalidomide has demonstrated prior antitumor activity, prompting investigation in HCC.
Purpose of the Study:
- To evaluate the safety and efficacy of thalidomide in patients with unresectable or metastatic HCC.
- To assess thalidomide's role in patients whose disease is refractory to systemic chemotherapy.
Main Methods:
- Eight patients with measurable, metastatic HCC progressed on prior chemotherapy were enrolled.
- Oral thalidomide was administered at 200 mg/day, with response assessed bi-monthly.
Main Results:
- One partial response (12.5%) and four stable disease cases were observed.
- The most frequent toxicity was somnolence; one patient discontinued due to grade 3 somnolence.
- Median treatment duration was 152 days.
Conclusions:
- Thalidomide may offer feasible disease stabilization for metastatic HCC patients.
- Further investigation into thalidomide dose escalation or combination therapy is recommended.
